Entana Pharmaceuticals Releases Study Results of Hepatitis Treatment in Japanese Patients

Japan has one of the highest rates of hepatitis C in the industrialized worldRelated Stocks: ENTA, ABBV,.....»»

Category: worldSource: nytJan 11th, 2017

Novartis Buys Selexys on Favorable Phase II Data on SelG1

Novartis (NVS) acquired Selexys Pharmaceuticals following the receipt of results from the phase II SUSTAIN study for the treatment of patients with SCD. Swiss drug maker Novartis AG NVS announced that it has acquired Selexys Pharmaceuticals Cor.....»»

Category: topSource: zacksNov 22nd, 2016

AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb

AbbVie Inc. (ABBV) announced positive results from the phase IIIb study, Garnet, on a combination of its hepatitis drugs Viekirax and Exviera for the treatment of patients with hepatitis C virus (HCV) infection without liver cirrhosis. AbbVie I.....»»

Category: topSource: zacksSep 26th, 2016

Paratek Antibiotic Candidate"s Phase III Data Favorable

Paratek Pharmaceuticals, Inc. (PRTK) announced positive results from a phase III study (OASIS-2) comparing its antibiotic candidate omadacycline to Pfizer Inc.'s (PFE) Zyvox for the treatment of acute bacterial.....»»

Category: topSource: zacksJul 18th, 2017

Why Ionis Results Today Support A Pair Trade With Alnylam

Following Ionis Pharmaceuticals Inc (NASDAQ: IONS)'s announcing positive results in a late-stage study of its anti-sense oligonucleotide, inotersen, dubbed IONIS-TTRRx, in patients with transthyretin familial amyloid polyneur Latest Ratings for ALN.....»»

Category: blogSource: benzingaMay 15th, 2017

ResMed"s Study Results for Central Sleep Apnea Hold Promise

ResMed Inc. (RMD) recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA). Medical device c.....»»

Category: topSource: zacksApr 11th, 2017

ANTH"s (ANTH) Blisibimod Completes Dosing in Phase III Study

Anthera Pharmaceuticals, Inc. (ANTH) recently announced the completion of dosing in a phase II study, BRIGHT-SC. The study evaluated key pipeline candidate blisibimod for treatment of patients with IgA nephropathy (IgAN.....»»

Category: topSource: zacksApr 11th, 2017

Disappointment In Corvus Pharma Understandable, But Selloff May Have Been Overdone

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) nearly half its value Tuesday following the release of interim results of its Phase 1 study of CPI-444, designed to treat patients with advanced cancers. Latest Ratings for CRV.....»»

Category: blogSource: benzingaApr 5th, 2017

Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate

Spectrum Pharmaceuticals (SPPI) recently announced that it has initiated a phase II trial to evaluate its pipeline candidate, poziotinib for the treatment of non-small cell lung cancer patients. Sp.....»»

Category: topSource: zacksMar 31st, 2017

How La Jolla’s Low Blood Pressure Treatment Is Driving New Highs

La Jolla Pharmaceutical saw its shares skyrocket on Monday after top-line results from its late-stage study of patients with catecholamine resistant hypotension......»»

Category: blogSource: 247wallstFeb 27th, 2017

Catabasis shares plummet on Duchenne trial failure

Cambridge-based Catabasis Pharmaceuticals is poised to lose most of its market value after announcing disappointing results from a study of its Duchenne muscular dystrophy treatment late Tuesday. Catabasis (Nasdaq: CATB), which had 37 employees t.....»»

Category: topSource: bizjournalsJan 31st, 2017

Marinus Releases Positive Preliminary Data from CDKL5 Study

Marinus Pharmaceuticals, Inc. (MRNS), announced positive preliminary data from the initial CDKL5 pediatric patients enrolled in its ongoing phase II study.....»»

Category: topSource: zacksJan 24th, 2017

Pfizer"s Humira Biosimilar Meets Primary Endpoint in Study

Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis. .....»»

Category: topSource: zacksJan 6th, 2017

Triad firm reports positive results for study of diabetes treatment

High Point-based biopharmaceutical company vTv Therapeutics Inc. announced that it has completed a successful phase 2 study that evaluated its oral therapy used to treat Type 2 diabetes patients. The 12-week study conducted across 30 centers in the U.S. .....»»

Category: topSource: bizjournalsDec 16th, 2016

Cambridge gene therapy firm Voyager gets positive results on Parkinson"s treatment

A Parkinson’s treatment developed by Cambridge gene therapy firm Voyager Therapeutics helped patients improve motor function in a small, early-stage study, the company said Wednesday. Voyager (Nasdaq: VYGR), part of a new wave of gene editing firms in .....»»

Category: topSource: bizjournalsDec 7th, 2016

Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures. P.....»»

Category: topSource: zacksDec 2nd, 2016

Testing of Treatment for Cystic Fibrosis Patients Begins

Results of study will be released in the —nd quarter of —…–7Related Stocks: GLPG, ABBV, VRTX,.....»»

Category: blogSource: gurufocusNov 29th, 2016

Adamas (ADMS) Parkinson"s Disease Drug Positive in Phase III

Adamas (ADMS) presented data from the phase III EASE LID 3 study on ADS-5102 for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients. Adamas Pharmaceuticals, Inc. ADMS announced positive data from the phase III study &n.....»»

Category: topSource: zacksSep 21st, 2016

Why Aeri Pharma Won So Big on a Single Trial

Shares of Aeri Pharmaceuticals skyrocketed early Thursday after the company issued positive results on its intraocular pressure (IOP) treatment in patients with glaucoma......»»

Category: blogSource: 247wallstSep 15th, 2016

AcelRx Stock Jumps 20% After Positive Results From Its Trial On ARX-04

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) disclosed that its investigational product candidate ARX-04 provided solid tolerance level in an open-label Phase three trial for post operative acute pain treatment. This included elderly patients, as well as, or.....»»

Category: earningsSource: benzingaSep 15th, 2016

Aerie Pharma shares jump more than 60% on eye-drug study results

Aerie Pharmaceuticals Inc. shares skyrocketed in the extended session Wednesday after the drug discovery company's treatment for lowering fluid pressure inside the eyeball yielded promising results. Aerie shares jumped 61% to $34 on heavy volume. In a la.....»»

Category: topSource: marketwatchSep 14th, 2016